Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

The company’s latest RSV vaccine is yet to show promising sales. This has weighed on MRNA stock, down 52% since early 2024. Even if we look at a slightly longer period, the changes in MRNA stock ...

which MRNA is developing in partnership with Merck (MRK), to lift MRNA stock this year. Ellison's Statement on Potential Cancer Vaccines Last week, Oracle Chairman Larry Ellison asserted that AI ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

MRNA is also committed to becoming a more efficient organization, given that it reduced its operating costs by more than 25% in 2024, compared to 2023. Investors are bullish on the stock because ...